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Metal oxide nanoparticles have emerged as exceptionally potent biomedical
sensors and actuators due to their unique physicochemical features. Despite
fascinating achievements, the current limited understanding of the molecular
interplay between nanoparticles and the surrounding tissue remains a major
obstacle in the rationalized development of nanomedicines, which is reflected
in their poor clinical approval rate. This work reports on the nanoscopic
characterization of inorganic nanoparticles in tissue by the example of
complex metal oxide nanoparticle hybrids consisting of crystalline cerium
oxide and the biodegradable ceramic bioglass. A validated analytical method
based on semiquantitative X-ray fluorescence and inductively coupled plasma
spectrometry is used to assess nanoparticle biodistribution following
intravenous and topical application. Then, a correlative multiscale analytical
cascade based on a combination of microscopy and spectroscopy techniques
shows that the topically applied hybrid nanoparticles remain at the initial site
and are preferentially taken up into macrophages, form apatite on their
surface, and lead to increased accumulation of lipids in their surroundings.
Taken together, this work displays how modern analytical techniques can be
harnessed to gain unprecedented insights into the biodistribution and
biotransformation of complex inorganic nanoparticles. Such nanoscopic
characterization is imperative for the rationalized engineering of safe and
efficacious nanoparticle-based systems.
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1. Introduction
Nanoparticle-based materials are increas-
ingly used in the biomedical field due
to their versatility and exclusive proper-
ties. Nanoscale engineering has given
rise to a whole new toolset for the de-
sign of innovative biomedical materials.[1]
It enables the bottom-up synthesis of
hierarchical structures with ultrahigh
precision,[2] which opens the possibility to
directly engineer the interactions of struc-
tures with the surrounding environment
across a wide range of length scales.[3]
However, steering the material-biology
interplay at the nanoscale implies a detailed
understanding of the reactions occur-
ring in the biological environment upon
nanoparticle exposure and vice versa.[4]
Most recent developments in the
biomedical field have shifted the focus from
complex, often over-engineered solutions
to more robust, easy-to-use approaches.[5]
Based on this shift, many scientists have
embraced metal and metal oxide nanopar-
ticles for a wide spectrum of applications
such as sensing, diagnosis, delivery, and
as pharmacologically active agents.[6] Such
nanoparticles exhibit well-documented direct and robust
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bioactivity, which does not rely on complex organic post-
modification. Metal and metal oxide nanoparticles have shown
great potential as contrast agents for different medical imaging
techniques,[7] cancer treatment,[8] and drug delivery.[9] Metal
oxide nanoparticles are especially relevant for the wound man-
agement field, where the advent of nanomaterials enabled
easy-to-use solutions that eliminate the need for cross-linking
reactions or in vivo polymerization.[10] This is best illustrated
by a recent example where Leibler and colleagues[11] have in-
troduced the concept of nano-bridging, which can be employed
to achieve tissue adhesion by a mere physical phenomenon.[12]
Additionally to binding tissue, metal oxide nanoparticles also
allow the incorporation of bioactive entities. While there is a
variety of materials[13] and ions[14] of interest, especially bioactive
ceramics have been shown to improve wound healing in nu-
merous ways.[15] Recently, the adhesive and bioactive properties
of such nanoparticles have been combined in the development
of ceria (CeO2)/bioglass (45S5, BG) hybrid nanoparticle-based
tissue glues. Topically applied aqueous suspensions of these
nanoparticles have been shown to significantly increase the
blood perfusion and the survival of full-thickness skin flaps
in a rat model by promoting adhesion and angiogenesis.[16]
Various advantages of such nano-enabled solutions compared to
current wound closing techniques have been demonstrated.[12]
In general, metal oxide nanoparticles are being researched
intensely and show great potential in biomedicine, yet they have
a difficult stand in terms of translation to clinics. While some
metal oxide nanoparticles have received market approval,[17]
especially as imaging agents,[18] their translation has been slow
in recent years.[19,20] For many metal oxide nanosystems there
are safety concerns regarding their poor degradability and the
limited understanding of their in vivo fate.[21,22] The detailed un-
derstanding of the interactions of nanoparticles with biological
entities, especially their redistribution and degradation, remains
pivotal for the safe and efficacious development of nanoparticle-
based products in general.[23] The inability to measure and
assess this interplay renders both improvement and regulation
of nanomedicine extremely challenging. These challenges are
reflected in the low approval rates of nanomedicines, despite
immense investments by academia and industry in recent
years.[19,20]
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In contrast to the much-studied intravascular application, topi-
cal application of adhesive metal oxide nanoparticle suspensions
has the prospect to limit the re-distribution of the nanoparticles to
non-target sites.[24] Reaching such an understanding, however, is
not straightforward, especially for a complex system such as the
aforementioned hybrid, which contains a stable, crystalline (ce-
ria) and a biodegradable, amorphous (BG) phase in one nanopar-
ticulate entity.[25] Current medical imaging technologies do not
have the spatial resolution required to yield information on a
single-particle scale. Most studies that address in vivo nanopar-
ticle fate use computer X-ray tomography with relatively poor
sensitivity or magnetic resonance imaging,[26] that is limited at
around 30 µm.[27] Higher resolution analysis including histol-
ogy, X-ray and fluorescence imaging, are typically performed on
ex vivo tissues.[28] These techniques have typical resolutions of
10 µm (X-ray microtomography, laser-induced breakdown spec-
troscopy), or 1 µm in high-resolution 2D micro X-ray fluores-
cence (𝜇XRF).[29] Laser ablation inductively coupled plasma mass
spectrometry (LA-ICP-MS) reaches high sensitivities of 500 ppb
for heavy elements (e.g., Au), however, typical spot diameters
are limited to 1–10 µm.[29] Most of the methods with ultrahigh
sensitivity are either based on transmission electron microscopy,
which gives information about single-particle distribution in the
biological sample, but has a limited field of view, or on elemen-
tal analysis of the bulk and thus do not yield spatially resolved
information.[30] In other words, there is a sub-micrometer local-
ization gap for nanoparticles after in vivo application. Not only
localization of the applied nanoparticles is important, but also
the evaluation of their chemical environment and degradation.
Physicochemical changes at the nanoscale, such as particle up-
take and agglomeration, phase transformation, and degradation
are pivotal, yet difficult to monitor.[21–31]
Here, we report on a nano-analytical cascade that can bridge
the nanoparticle localization gap and allows the assessment of
their physicochemical properties and their local metabolic im-
pact. We selected complex nanoparticles used as tissue adhesives
as an analytically very challenging but medically relevant material
to showcase the opportunities and limitations of the proposed
analytical imaging cascade. These metal oxide nanoparticle
hybrids consisting of bioglass and ceria (BG/ceria) were applied
either topically as tissue glues to the subcutis in a rat skin flap
model or systemically. First, we present the physicochemical
characterization of the as-prepared metal oxide hybrid nanoparti-
cles (BG/ceria) prior to application. Following topical application
in vivo, we then report on the micro- and nano-analytical assess-
ment of the particle fate and biotransformation by cutting-edge
analytical technologies. We present results on the compositional
analysis of these complex nanoparticle hybrids along with
biodistribution data at unprecedented sensitivity and resolution.
We demonstrate how information on the fate of nanoparticles
can be obtained by retrieving molecular fingerprint information
using a combination of hyperspectral Raman spectroscopy
mapping, time-of-flight secondary ion mass spectrometry (TOF-
SIMS) imaging and density-dependent color scanning electron
microscopy (DDC-SEM), thus bridging the aforementioned
localization gap. The analytical cascade described in this work
is directly translatable to most other inorganic nanoparticle
systems and shows how biochemically complex nanomaterials
can be understood and their interaction with and fate within
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Figure 1. a) BG/ceria hybrid nanoparticles were produced using flame spray pyrolysis. Scanning transmission electron micrograph overlaid with energy-
dispersive x-ray spectroscopy maps show the elemental distribution within the particles. b) Ceria recovery in the hybrid nanoparticles was quantified
using different elemental analysis techniques. The standard digestion method using hydrofluoric acid (HF) fails due to the formation of CeF3. Digestion
using a mixture of H2O2 and HNO3 showed high recovery rates for both bare particles and on particle-spiked tissues. c) The nanoparticles in suspension
were applied to the subcutis in a rat skin flap model. d) Biodistribution of BG/ceria hybrid nanoparticles 7 days after application (intravenous injection
into the inferior vena cava or topical application to the subcutis). In the case of the topical application, more than 99.96% stayed at the initial site of
application (n = 3).
their host can be comprehended. Such in-depth characterization
and analysis provide additional insights into the material-biology
interplay, which are inaccessible by conventional methods (his-
tological and immunological assays and elemental analysis) and
will support the rational development and regulation of a wide
range of nanomaterials for biomedical applications.
2. Results and Discussion
Flame spray synthesis enables the scalable,[32] sterile and well-
controlled synthesis of complex metal oxide nanoparticles with
a diversity of compositions and architectures.[33–34] Since the
stoichiometry of the nanoparticle product made through flame
spray pyrolysis corresponds to that of its precursor solution,
this technique offers a straightforward way to produce hybrid
mixed metal oxide nanoparticles in a tightly controlled scalable
process, fulfilling major prerequisites for clinical nanomaterial
manufacturing.[35] Here, BG/ceria hybrid nanoparticles synthe-
sized by scalable one-step flame spray pyrolysis were charac-
terized in their as-prepared state prior to application in vivo.
The techniques utilized for the as-prepared characterization of
this complex system are applicable to a wide range of inorganic
nanoparticles. While the presented analytical imaging cascade is
applicable to any type of nanoparticle administration, the current
study focuses on the analysis of topically applied nanoparticles,
which is the intended route of administration for these unfunc-
tionalized BG/ceria hybrid nanoparticles.
2.1. Characterization of As-Prepared Nanoparticles
High-resolution scanning transmission electron microscopy
(STEM) and energy-dispersive X-ray spectroscopy (EDXS) show
the presence of 20–40 nm crystalline ceria nanoparticles sur-
rounded by amorphous sub-10 nm BG nanoparticles (Figure 1a;
Figure S1, Supporting Information). This phase separation
observed in the hybrid nanoparticles is due to the production
method which includes two independent precursor inlets, which
allow the primary precursor, ceria, to partially oxidize before
meeting the secondary precursor (bioglass).[25] The obtained
morphology of the hybrid oxide nanoparticles is characteristic of
flame spray synthesized nanomaterials. X-ray diffraction (XRD)
measurements of the hybrid materials confirm the presence of an
amorphous phase as well as a crystalline ceria content of 85.64%,
estimated using NiO as an internal standard (Figure S2, Support-
ing Information). The crystallite size of ceria was estimated by
the Scherrer equation as 22 nm and is in good agreement with
the electron micrographs. The specific surface area determined
by the Brunauer Emmett Teller (BET) method was 43 ± 0.2
m2 g−1 and the particle size was estimated as dBET = 25 nm.
Additional physicochemical characterization by FTIR, Raman
and XPS of the as-prepared nanoparticle hybrids can be found
in Figure S2 in the Supporting Information. X-ray photoelectron
spectroscopy (XPS) indicates that ceria is present predominantly
as Ce4+ (Figures S2 and S3, Supporting Information).[25] The
organic content of the nanoparticle hybrids was determined by
thermogravimetric analysis mass spectroscopy (TGA-MS) and
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CHN elemental analysis. The total carbon content of as-prepared
nanoparticles was 1.5 wt%, which is in line with carbon contents
of similarly produced silica nanoparticles.[36] The compositional
analysis of the BG/ceria (Ce, Ca, Na, P, Si) particles is analytically
challenging, especially because the hydrofluoric acid typically
used for the digestion of silica-based materials forms insoluble
CeF3 with the cerium present in the sample. If an established
digestion method[37] for silica-containing ceria hybrid materials
based on a mixture of HNO3/H2O2/HCl/HF was used, only
62% of the theoretical cerium amount was found (Figure 1b).
Therefore, the composition of the BG/ceria hybrid has been
determined by two complementary methods, wavelength dis-
persive X-ray fluorescence (WD-XRF, not requiring chemical
digestion) and inductively coupled plasma optical emission
spectrometry (ICP-OES) using a microwave-assisted digestion
method based on HNO3/H2O2. Elemental analysis of the hybrid
nanoparticles by ICP-OES using an HF-free digestion route
yields 85.87 wt% ceria which is in excellent agreement with the
nominal ceria content calculated from the liquid precursors of
(86.37 wt%) as well as the content determined by XRD (relative
deviation: 0.3 wt%) and WD-XRF (relative deviation: 4 wt%).
Before in vivo application, the nanoparticles were dispersed in
physiological saline. The hydrodynamic diameter in physiologi-
cal saline was 273 ± 6 nm (dispersity of 0.37) and the zeta po-
tential reached a value of −27 mV at physiological pH (7.3) and
−25 mV at lysosomal pH (4.5), in line with previously reported
nanoparticle-based systems with similar composition. Compa-
rable values were found upon contact with other dispersants,
with sizes slightly larger and zeta potential values slightly less
negative after exposure to human plasma (Table S1, Supporting
Information).[38,39]
2.2. In Vivo Application and Biodistribution Measurements by
Elemental Analysis
In order to validate the ICP-OES and ICP-MS protocols on the
tissue samples, they were applied to nanoparticle-spiked tissue
samples to measure the recovery for CeO2. For a reverse aqua re-
gia digestion protocol, recovery rates ranged from 92.8% to 103%.
For HNO3/H2O2 digestion, recovery rates between 95.2% and
97.9% were found for nanoparticle-spiked tissue samples. The
latter protocol was deemed more robust and used for subsequent
digestions. A lower limit of detection was determined (8.3 µg g−1
tissue for ICP-OES and 0.01 µg g−1 of tissue for ICP-MS). Ad-
ditionally, nanoparticle degradation in lysosomal conditions (pH
4.5) was assessed over a period of 14 days by measuring Ce and
Si ion dissolution (Figure S4, Supporting Information). Very low
Si release (<2%) from the BG part of the nanoparticles was mea-
sured and close to no Ce release (<0.1%). This finding is in good
agreement with literature reports showing slow degradation of
ceria in intracellular environments[40] and indicates that the ma-
jority of Si and Ce is present as nanoparticles.
Figure 1c illustrates the topical application of nanoparticle dis-
persions (0.1 mg of nanoparticles per cm2) to the subcutis in rats.
Additionally, equivalent nanoparticle doses were applied as bo-
lus intravascular (IV) injection into the inferior vena cava. After
seven days, organs were harvested and the cerium concentration
in tissue was determined by ICP-OES and ICP-MS, using the val-
idated elemental analysis method.
Of the IV injected nanoparticles, 68% accumulated in the liver
(Figure 1d) and significant amounts of nanoparticles were also
detected in the spleen (18 wt%) and the kidneys (13 wt%). No-
tably, cerium was also found in the brain, accounting for ≈1
wt% of the applied nanoparticle dose. The crossing of the blood–
brain barrier has previously been reported for ultrasmall ceria
nanoparticles,[41,42] however, the elevated values could also be
caused by small amounts of dissolved Ce3+ ions. The results
from the IV application show a characteristic distribution where
most of the nanoparticles are found in the liver, spleen and kid-
ney, which is in agreement with other studies.[43,44] Notably, the
developed analytical method enables sensitive quantification of
these complex metal oxide nanoparticles after in vivo adminis-
tration. Since the BG/ceria nanoparticles are intended to be used
as topical agents, their biodistribution was assessed after topi-
cal application using the same protocol. In stark contrast to the
IV administration, around 99.96 wt% of the applied nanoparti-
cles were found in the skin tissue at the original site of applica-
tion (Figure 1d). The remaining 0.04 wt% were found in the liver
(0.019 ± 0.005 wt%), the kidney (0.008 ± 0.002 wt%), the spleen
(0.007 ± 0.001 wt%), and the brain (0.010 ± 0.011 wt%). Assum-
ing uniform distribution over measured organs, an estimated
104.7%± 10.6% of the initial dose (2.7 mg) was found in the sam-
pled organs. In brief, after applying the BG/ceria nanoparticles in
rats via their intended topical administration route, a large ma-
jority of them has stayed where applied while a minimal dose has
been distributed to the organs. The elemental analysis study car-
ried out here illustrates how inorganic nanoparticles, even com-
plex ones, can be traced in different organs in a label-free manner.
2.3. Nanoparticle Localization by µCT
After localizing the bulk of the topically applied nanoparticles
at the application site, skin flap biopsies were collected and
subjected to high-resolution microcomputed tomography (µCT)
analysis. Agglomerates of high-density particles can be identified
as bright spots in the CT images as seen in Figure 2 and Figure
S5 (Supporting Information). The nanoparticles are distributed
on the subcutis of the rat as a thin layer (≈50 µm) at the initial
site of the application.
2.4. Identification of the Cellular and Biochemical Environment of
the Nanoparticles
After identifying relevant regions by CT, histological sections
were cut from skin biopsies and stained with hematoxylin &
eosin (H&E), CD68 (macrophages) and CD31 (endothelial cells),
respectively (see Figure 3a; Figure S6, Supporting Informa-
tion). In agreement with previous reports,[45] the identification of
nanoparticles in histological samples is not straightforward and
therefore correlative X-ray fluorescence mapping was employed
to localize regions with high cerium concentrations (Figure 3b,c).
XRF mapping of the entire biopsy cross-section indicates the
accumulation of cerium in the ventral part of the skin flap biopsy.
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Figure 2. Reconstructed computer tomographs of a) a large part of a rat skin flap and b) a smaller rat skin biopsy. Green frames indicate the same
region. High-intensity pixels are colored red and represent nanoparticles. The nanoparticles are easily identifiable and are located along the subcutis of
the rat.
Overlay with the CD68 stained tissue section indicates a high
number of macrophages in the nanoparticle-rich tissue region.
The two main shortcomings of XRF mapping, namely limited
spatial resolution (≈10 µm) and missing information on organic
compounds, can be compensated by Raman spectroscopy and
time-of-flight secondary ion mass spectrometry. ToF-SIMS anal-
ysis of the tissue flap indicates ceria (CeOx in red, Figure 3d) and
phosphate (POx in orange, Figure 3e) rich regions surrounded by
an organic matrix. Label-free Raman spectroscopy mapping on
histological sections (Figure 3f–k) allows both the identification
of particles and organics by their spectral fingerprint.
To further investigate the immediate surroundings of the
nanoparticles, hyperspectral image unmixing for the Raman
spectroscopic data based on non-negative matrix factorization
(NMF) was performed.[46] The abundance map of ceria was con-
structed by unmixing the Raman spectra in the 200–600 cm−1
region where the principal peak of ceria (465 cm−1) is present.
Similarly, lipids and cholesterol components were extracted by
performing NMF in the 600–1800 cm−1 biological “fingerprint”
region[47] where several characteristic peaks of lipids and choles-
terol are present. (Figure 3i–k).
Increased levels of lipids and cholesterol were found around
the nanoparticles compared to untreated samples and tissue
distant from the nanoparticles (Figure 3i–k), with the 2D spa-
tial correlation of ceria and lipid signatures being 60%. This
increase of lipid occurrence around BG/ceria nanoparticles is
in good agreement with previous in vitro cell culture experi-
ments with BG where it was hypothesized based on gene ex-
pression analysis that BG upregulates the mevalonate and sterol
biosynthesis pathways.[48] ToF-SIMS based analysis of the or-
ganic constituents in the particle-containing tissue region also
showed characteristic signatures of phosphocholines, cholesterol
and fatty acids in the proximity of the nanoparticles in support
of the Raman findings (Figure S7a–d, Supporting Information).
The biomolecular environment and impact of nanomedicines
is of high clinical interest. The measurements on the BG/ceria
nanoparticles after in vivo application showcase the use of mod-
ern spectroscopic techniques to shine light on biological pro-
cesses in close vicinity of metal oxide nanoparticles (compare
Table S2 in the Supporting Information). The accumulation of
lipids around the nanoparticles and their biological relevance
with regard to angiogenic and tissue regenerative properties of
the nanoparticles are yet to be understood.[16]
2.5. Nanoparticle Biotransformation
Apart from the location and surroundings of therapeutic
nanoparticles, their physical and chemical state is highly
important to holistically understand their fate. In living organ-
isms, these states are subject to a modification process called
biotransformation.[49] In the following, we assess the biotrans-
formation of the topically applied BG/ceria nanoparticles. An
overlay of the histology with the spectroscopic (XRF, ToF-SIMS,
and Raman) data further indicates that the nanoparticles are
found at the initial site of application (Figure 2–4). Biological in-
formation from H&E stained tissue sections (Figure 4a–c) can be
completed by ToF-SIMS (Figure 4d). ToF-SIMS showed a charac-
teristic ceria signal from the particles embedded in the surround-
ing biological matrix (proteins and lipids) only after sputtering
away a thin top layer with oxygen. The depth profiling indicates
that the ceria is covered by a thin (<5 nm) layer of cerium-free
material. Negative and positive polarity measurements on said
layer indicate phosphate (PO−, PO2−, and PO3−) and Ca3PO5
+,
Ca4PO6
+ fragments respectively. These compounds suggest cal-
cium phosphate mineralization of the BG on the particle surface.
Higher magnification Raman peak maps of the CeO2 F2g signal
(465 cm−1), CH/CH2 vibrations (1448 cm
−1), and the amide I
band (C O, 1655 cm−1) allow localization of ceria, as well as lipid
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Figure 3. a) Macrophage-stained (CD68) histology section of skin rat tissue. b) XRF measuring spots and Ce signal. c) Overlay of (a) and (b). The Ce
distribution is limited to the subcutaneous region of the skin and is maximal (green) around the macrophages (brown staining). Blue frame indicates
ToF-SIMS measurement region d) ToF-SIMS map with CxHy (green) as a tissue marker, SiOx (blue) as a substrate marker, and ceria (CexOyHz, red).
e) The same region with CN + CNO (green), O + OH (blue) and phosphate (PO2 + PO3, red). The co-location of ceria and phosphate indicates the
mineralization of the BG component. f–k) Raman spectroscopy signatures of tissues from nanoparticle-treated and untreated rats. Non-negative matrix
factorization (NMF) was used to separate different constituents, compare Figure S8 in the Supporting Information. f) Average Raman spectra of the
as-prepared nanoparticles versus treated tissue. Raman intensity of treated tissue is normalized according to the peak intensity of ceria at 465 cm−1. The
average spectrum can be decomposed into an inorganic part <600 cm−1 and a biological part >600 cm−1. g) The lipid component spectra of the treated
and untreated tissue samples show a higher occurrence of lipid components in the treated sample. The shaded area denotes the standard deviation
from bootstrap resampling. h) The lipid and cholesterol components that were extracted match their specific peaks reported in the literature.[60–62] i)
The ceria component shows the localization of the nanoparticles in the tissue sample. j) There is an increased lipid occurrence around the nanoparticles.
k) Additionally, increased amounts of cholesterol are found in the particle region.
and protein-rich compounds associated with the particles and the
surrounding tissue with an effective resolution of around 500 nm
(Figure 4e–g).
The maps give a strong indication that the nanoparticles
are present in well-confined agglomerates with a characteristic
length of 10 µm in line with the previous observation of increased
macrophage presence in ceria-rich regions. Additionally, charac-
teristic Raman signatures at 960 cm−1 (symmetric stretching of
the orthophosphate groups PO4
3− in apatite) indicate in situ min-
eralization and formation of apatite on the particles (Figure 4f).
As seen on a Raman peak map overlay, this mineralization coin-
cides well with the ceria distribution (Figure 4i) and is in line with
the ToF-SIMS results. No formation of CePO4 was found on the
surface (no peak at 973 cm−1, stretching vibrations of the -PO4
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Figure 4. a–c) Histological images of rat skin tissue. Same-color frames indicate approximate region. d) Corresponding ToF-SIMS map with proline
(blue) as a tissue marker, Si (green) as a substrate marker, and Ce (red). e) Raman merged spectral map of the same region showing CeO2, f) CH/CH2
(lipids), g) amide I (proteins), and h) POx (apatite). i) Overlay of the previous maps with CeO2 in red, CH/CH2 in blue, amide I in green, and POx in
blue. j) Electron micrograph of the same region confirms particle distribution around a blood vessel.
unit of monoclinic CePO4). This absence of CePO4 is in good
agreement with previous studies using X-ray absorption spec-
troscopy showing Ce reduction and CePOx formation primarily
for small Ce nanoparticles and almost no reduction for ceria par-
ticles with a size of 20–30 nm.[50] The formation of apatite upon
exposure to body fluids is in line with previous in vitro studies,
which report the detection of apatite on BG/ceria hybrid nanopar-
ticles following exposure to simulated body fluid.[25] The forma-
tion of apatite on BG particles is also well described following in
vivo application.[51]
2.6. Electron Microscopy Observations on Nanoparticles in
Tissue
Since the resolution of the Raman spectroscopy maps is
diffraction-limited (the effective lateral resolution is around
500 nm), tissue sections were also analyzed by electron mi-
croscopy (Figure 4j and 5). Backscattering electron (BSE)
micrographs allow straightforward identification of the electron-
dense, ceria-containing nanoparticles in the tissue samples as
confirmed by EDXS (Figure S9, Supporting Information). Sec-
ondary electron (SE) images and backscattering electron (BSE)
images were collected from the same region in order to gather
information on both the tissue morphology and the elemental
contrast. These images were then assembled into RGB stacks; the
SE image was assigned to the green channel and the BSE data was
colored in red (Figure S10, Supporting Information). Overview
density-dependent color scanning electron micrographs images
were overlaid with corresponding histological micrographs
and allow straightforward identification of particle-rich regions
on the entire histology (Figure S11, Supporting Information).
These DDC-SEM micrographs at different magnifications again
strongly suggest that nanoparticles remain localized at the
primary site of application, i.e., the ventral part of the skin flap.
DDC-SEM imaging at higher magnification allows clear identifi-
cation of accumulated nanoparticles in tissue sections based on
their density and structural characterization at nanometric reso-
lution (Figure 5c). In contrast to TEM analysis, DDC-SEM allows
analysis of a much wider field of view and provides a powerful
tool for the straightforward identification of nanoparticle-
rich regions in histological sections. Overlaying these with
DDC-micrographs with CD68-stained sections confirms the
co-localization of the particle agglomerates and CD68-positive
macrophages (Figure S9c,d, Supporting Information). All
nanoparticles are densely packed in the macrophages, whereas
almost none are found in the connective tissue. To gain more
insights into the particle localization, a trench was cut by focused
ion beam milling confirming that the nanoparticles are indeed
localized within membrane-bound structures (Figure 5b,c). The
chemical composition of the nanoparticles was again confirmed
by EDXS, which shows emissions characteristic for cerium,
phosphorus, and silicon (Figure S9, Supporting Informa-
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Figure 5. a) Density-dependent color secondary electron micrograph of nanoparticle-containing tissue macrophages next to a blood vessel. Nanopar-
ticles show up in yellow (compare EDXS in Figure S8 in the Supporting Information). b) Focused-ion beam cut trench giving access to cross-sectional
imaging of a c) nanoparticle-containing macrophage. Red arrows indicate the same region.
tion). This finding confirms the hypothesis that macrophages
take up most nanoparticles and shows how they are densely
packed within them. The co-localization of nanoparticles with
macrophages has been previously observed for metal and metal
oxides.[43–52]
The proposed imaging and analysis cascade enabled the trac-
ing of topically applied inorganic nanoparticles from organ biop-
sies (10−2 m) to subcellular structures (10−8 m). While this in-
depth analysis confirms the presence of cerium, silicon, and
phosphorus at the initial site of application, the current study
also illustrates that crystalline, high-z, poorly soluble compo-
nents (such as ceria) are easier to trace compared to amorphous,
light and potentially degradable constituents (e.g., BG). This cas-
cade is transferable to a wide range of metal and metal oxide
nanoparticles (see Table S2 in the Supporting Information).
3. Conclusions
In this work, we have demonstrated the integration of cutting-
edge imaging and analysis techniques to trace the location and
alteration of nanoparticles in tissue following topical application.
The cascade provides insights into the nanoparticle intratissural
distribution which is inaccessible by solely conventionally used
techniques, such as histology and elemental analysis. The stud-
ied nanoparticles showed very low clearance and stayed at the
site of application for more than a week. However, there are clear
physicochemical changes measurable, showing bioactivity and
biotransformation of the investigated particles. Notably, the pro-
posed analytical cascade capitalizes on label-free methods and
thus no modification to the active agents is needed. The inorganic
nanoparticles and their degradation products, as well as alterna-
tions in the surrounding tissue, can be assessed directly instead
of relying on surrogate markers. Additionally, the multiscale cor-
relation of different imaging and analysis techniques proposed
here is applicable to a wide range of inorganic nanomedical
agents due to the versatile nature of the used techniques. In
the face of an ever-growing number of inorganic nanomedicinal
products (including more exotic materials such as HfO2) on their
way to clinics, this cascade can provide a basis for both the im-
provement of their effectiveness and their regulation. We believe
that the demonstrated multiscale assessment of nanoparticle-
tissue and cell interactions will facilitate the rationalized and sus-
tainable design and regulation of new nanomaterials.
4. Experimental Section
Nanoparticle Synthesis: Chemicals were purchased from Sigma
Aldrich if not stated otherwise. BG/ceria hybrid nanoparticles were pro-
duced by liquid-feed flame spray pyrolysis according to previously pub-
lished methods.[25] The particles were produced in a two-nozzle setup
(see Matter et al.,[25] Figure S1, Supporting Information): Bioglass was
used as secondary precursor and ceria as primary precursor. 6 mL min−1
of primary precursor (total metal ion concentration 0.3 m in THF; 40 wt%
calcium acetylacetonate hydrate, 37 wt% sodium 2-ethylhexanoate, 6 wt%
tributyl phosphate, 17 wt% HMDSO) was injected into a water-cooled
spray nozzle and dispersed by 5 L min−1 O2. The pressure drop at the
nozzle tip was approx. 1.5 bar. The spray was then ignited by a premixed
CH4:O2 (1.25 L min
−1:2.5 L min−1) flamelet. The entire flame and spray
were enclosed in a stainless steel tube and additionally sheathed with 20 L
min−1 O2. In addition, 11 cm down the particles stream and at an an-
gle of 45°, the secondary precursor (0.3 m Cerium(III) 2-ethylhexanoate in
THF) was fed at 3 mL min−1 through a second nozzle and dispersed with
N2 (13 mL min
−1). The as-prepared nanoparticles were collected from a
glass fiber filter mounted above the flame. Nanoparticle suspensions were
prepared by tip-sonication immediately before application.
Phyiscochemical Characterization: Scanning transmission electron mi-
crographs and elemental distribution maps of the as-prepared nanopar-
ticles were recorded on a Talos F200X TEM (Super-X EDS, 4 detector
configuration, FEI, USA) at an accelerating voltage of 200 kV. Samples
were mounted on a doubletilt holder and fixed using a molybdenum ring
and clamp. The data were processed using the software Velox 2.9 (FEI,
USA). X-ray diffraction patterns (XRD) were obtained with a Bruker D8
advance diffractometer (40 kV, 40 mA, CuKa radiation) at 2q = 10–70°. Dy-
namic light scattering (DLS) hydrodynamic size and zeta potential mea-
surements were conducted using a Zetasizer (Nano ZS90, Malvern Instru-
ments). To assess the effect of different fluid compositions, nanoparticles
were suspended in water (ddH2O), PBS, citrate buffer or human plasma
and incubated for 1 h. Nanoparticles were subsequently centrifuged and
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resuspended in 10% PBS for zeta potential measurements (Table S1, Sup-
porting Information). Raman spectra of the nanoparticles were recorded
on a WITec alpha 300R confocal Raman microscope, equipped with a
UHTS 300 Vis spectrometer and an Andor Newton EMCCD (see be-
low). Fourier transform infrared spectra were collected using a Varian
640-IR spectrometer. For X-ray photoelectron spectroscopy (XPS), the as-
prepared nanoparticles were analyzed on a PHI 5000 VersaProbe II instru-
ment (USA) with a monochromatic AlK𝛼 X-ray source. Energy resolution
was at 0.8 eV per step at a pass-energy of 187.85 eV for survey scans and
0.125 eV per step and 29.35 eV pass-energy for high-resolution region scan
of the Ce3d5 region, respectively. Carbon C1s at 284.5 eV was used as a
calibration reference. Data analysis was performed with CasaXP software
(Casa Software Ltd, United Kingdom). Peak fitting was done by adapta-
tions to Sims et al.[53] and Bêche et al.[54]
Animal Model and Tissue Procurement: The experimental animal study
was approved by the Ethics Committee for Animal Experimentation, Bern,
Switzerland (Approval number 89/16). The experimental section of the an-
imal model has been published before.[16] Briefly, A 9 cm × 3 cm dorsal
perforator-based flap was raised in Lewis rats and the interface was treated
with the nanoparticle suspension (in saline at a concentration of 2.7 mg
mL−1, dose per area: 0.1 mg cm−2, total dose per animal: 2.7 mg) in an at-
tempt to increase flap survival. The skin was closed with a running suture
and the flap was removed again for analysis seven days after treatment.
Various biopsies were harvested and fixed in formalin, while the remaining
of the flap was frozen in liquid nitrogen. For the systemic administration,
the nanoparticle suspension (total dose per animal: 2.7 mg) was applied
intravenously into the inferior vena cava. Tissues were again harvested
and frozen in liquid nitrogen or fixed in formalin. In addition to liver, kid-
ney, spleen, lung, brain and skin tissue also blood samples were collected
for further analyses.
Elemental Analysis: Carbon content of the nanoparticles was mea-
sured by using a carbon and sulfur analyzer (LECO CS-844). The nanopar-
ticles were burned at approximately 2000 °C and carbon was detected as
CO2 using an infrared cell.
Wavelength Dispersive X-ray Fluorescence (WDXRF) was used (Rigaku
Corporation; Tokyo, Japan) to measure Ce-content both directly on the
nanoparticle powder and a pressed pill. Ce-content in the different rat or-
gans was measured by taking organ samples of around 0.05–0.35 g. The
samples were then transferred to a PTFE container and mixed with 6 mL
65% HNO3 p. a. (Merck) and 1 mL 30% H2O2 p.a (Merck). The samples
were then digested in a microwave (MLS Start) and first measured on an
ICP-OES (Agilent 5110) and then on a QQQ-ICP-MS (Agilent 8800).
Particle Degradation in Lysosomal Buffer: The particles were suspended
in potassium citrate buffer at pH 4.5 to mimic lysosomal pH.[56] A concen-
tration of 50 µg mL−1 was used. The stock suspension was split in tubes
and left on a shaker at 37 °C. The tubes were collected at different days
and centrifuged at 20 000 × g for 30 min. Diluted samples were analyzed
by ICP-MS.
MicroCT: For microCT measurements, the tissue sample was
mounted in a polystyrene tube and kept in saturated ethanol atmosphere
during the measurement. X-ray microCT was performed using an EasyTom
XL Ultra 230-160 micro/nano-CT scanner (RxSolutions SAS, Chavanod,
France). The scans were performed using a Varian PaxScan 2520DX de-
tector. The tube was operated at 70 kV and 300 µA current for the large
skin flap sample and at 50 µA for the small biopsy. The voxel sizes of the
CT scans were 22.5 µm for the large sample and 3 µm for the small biopsy,
respectively. The images were acquired at 2 frames per second speed and
averaging 10 frames per projection.
Histology: Fixed skin biopsies were embedded in paraffin and cut
into sections. Selected sections were stained with hematoxylin-eosin.
Macrophages were identified by detection of the CD68 protein by immuno-
histochemical staining (Sophisto Lab, Muttenz, Switzerland). Light mi-
croscopy images of the sections were recorded using a Zeiss Primovert
microscope (Zeiss, Feldbach, Switzerland).
XRF Tissue Maps: X-ray fluorescence (XRF, Fischerscope X-RAY XDV-
SDD, Fischer Technology) has been used to estimate Ce at% along the
rat skin tissue. Histological sections mounted on (ITO-coated) glass
slides were deparaffinised and analysed. Mapping measurements were
performed at different points covering all the sample area. Concentration
maps were created by interpolation using TRIPACK.[57]
TOF-SIMS: ToF-SIMS analysis (TOF.SIMS.5 instrument from ION-
TOF GmbH) was performed to investigate the lateral distribution of the
BG/ceria nanoparticles within the tissue. Acetone-fixed histological sec-
tions mounted on (ITO-coated) glass slides were analysed. The data were
acquired in imaging mode to provide high lateral resolution (≈200 nm)
with 50 keV Bi3
++ primary ions (0.03 pA). An electron flood gun was used
to compensate for the charge accumulation in the insulating tissue mate-
rial. Secondary ions of positive and negative polarities were analyzed from
mass 1 to 800 mass units, and from surface areas of 500 × 500 µm2 with
a resolution of 256 × 256 pixels2. In order to increase the ceria signal in-
tensity, the bioglass was gently ablated by using 1 keV O2 sputtering for 1
second per scan (positive polarity only). A total of 1300 (400) scans were
acquired for positive (resp. negative) polarities to insure a reasonable sig-
nal over noise ratio.
Raman Microscopy: Raman measurements were performed as de-
scribed elsewhere.[58] Measurements were done either directly on
nanoparticles or histological sections that had been deparaffinized with
xylene. Measurements were performed on a WITec alpha 300R confocal
Raman microscope, equipped with a UHTS 300 Vis spectrometer and an
Andor Newton EMCCD. A linearly polarized 532 nm laser was used for
excitation. A 50× long distance objective was used (Zeiss, 50×/0.55 NA).
Single spectra were acquired with an integration time of 2 s and in at least
5 different locations. A laser intensity of 8 mW and integration times of 2s
were used
Raman Image Unmixing: Raman spectra were pre-processed by car-
rying out cosmic ray removal and baseline subtraction. The number of
components for running NMF was set to the number of significant princi-
pal components (PCs); the latter was estimated by self-referencing where
the PC correlation coefficients of two random subsamples were used (Fig-
ure S8, Supporting Information). NMF was then performed to construct
the component spectra and corresponding abundance maps from regions
200–600 cm−1 for ceria and 600–1800 cm−1 for lipids and cholesterol. All
computations were run on MATLAB R2018a.
Electron Microscopy: For secondary electron imaging, paraffin embed-
ded samples were dewaxed by immersion in pure xylene for two ten minute
intervals, dehydrated through a graded ethanol series (20, 30, 40, 50, 60,
70, 80, 90, and 100% (v/v)) and air dried. The slides were then silver
painted, carbon coated and secured on an SEM silver stub using conduc-
tive carbon adhesive tape. A Hitachi S-3499N SEM was used at a voltage
of 10 kV for acquisition of backscattered (BSE) and secondary (SE) elec-
tron micrographs. The density dependent colour SEM (DDC-SEM) micro-
graphs were produced by the superimposition of the BSE and SE images
using the Adobe Photoshop CC software.[59]
The focused ion beam (FIB) scanning electron micrographs on de-
paraffinized histology sections (coated with 10 nm C using Leica sputter
coater) were acquired using FEI Helios 660 G3 UC FIB/SEM (10 kV, 0.4 nA)
equipped with through-lens (TLD) backscattering detector. The trenches
of 15 µm wide and 10 µm deep were cut by operating the focused gallium
ion beam at 30 kV and varying the beam currents between 47 nA to 0.79 nA.
The subsequent images were acquired using a TLD detector using 10 kV
acceleration voltage and 0.4 nA electron beam current.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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